Angus brings over 25 years of R&D and Business Development experience to DDF
Angus joined DDF in July 2018 as CEO
Prior to joining the DDF, Angus worked at Celgene for almost 12 years. He started at Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters. In 2008, Angus moved to London as Head of Europe RA for 3 years to build out the function. Angus returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances, in 2011, where he built the alliance management function to manage over 60 collaborations and completed multiple innovative deals. In 2016, Angus became focused on deals, serving as Corporate VP of Business Development, leading a BD team running the transactions from deal inception to close as well as select acquisitions before leaving Celgene for the DDF. Angus previously worked at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the US Food and Drug Administration.
Angus received his undergraduate degree from the University of Richmond, then his Ph.D. in Anatomy & Immunology from the Medical College of Virginia and completed his post-doctoral training at the National Cancer Institute in Bethesda.
Outside of SV
Angus sits on the Board of MaRS Innovation, Tiaki Therapeutics, Cerevance and Rheostat Therapeutics.